Show simple item record

dc.contributor.advisorStephen Freedland (Duke University)
dc.contributor.authorMithal, Prabhakar
dc.contributor.authorAllott, Emma
dc.contributor.authorGerber, Leah
dc.contributor.authorReid, Julia
dc.contributor.authorWelbourn, William
dc.contributor.authorTikishvili, Eliso
dc.contributor.authorPark, Jimmy
dc.contributor.authorYounus, Adib
dc.contributor.authorSangale, Zaina
dc.contributor.authorLanchbury, Jerry S.
dc.contributor.authorStone, Steven
dc.contributor.authorFreedland, Stephen J.
dc.date2022-08-11T08:10:55.000
dc.date.accessioned2022-08-23T17:24:48Z
dc.date.available2022-08-23T17:24:48Z
dc.date.issued2014-12-01
dc.date.submitted2016-03-28
dc.identifier.citationInt J Urol. 2014 Dec;21(12):1209-14. doi: 10.1111/iju.12571. Epub 2014 Aug 5. <a href="http://dx.doi.org/10.1111/iju.12571">Link to article on publisher's site</a>
dc.identifier.issn0919-8172 (Linking)
dc.identifier.doi10.1111/iju.12571
dc.identifier.pmid25099119
dc.identifier.urihttp://hdl.handle.net/20.500.14038/49269
dc.description<p>Prabhakar Mithal participated in this study as a medical student as part of the Senior Scholars research program at the University of Massachusetts Medical School.</p>
dc.description.abstractOBJECTIVES: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. METHODS: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992-2006, biopsy samples were stained for PTEN expression by the PREZEON assay with > 10% staining reported as positive. Cox proportional hazards and log-rank models were used to assess the correlation between PTEN loss and clinical outcomes. RESULTS: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9-5.1, P = 0.10), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log-rank, P < 0.0001), and time from androgen deprivation therapy to castration-resistant prostate cancer (log-rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer. CONCLUSIONS: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25099119&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1111/iju.12571
dc.subjectBiomarkers, Tumor
dc.subjectBiopsy
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNorth Carolina
dc.subjectPTEN Phosphohydrolase
dc.subjectPrognosis
dc.subjectProstatic Neoplasms
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectTime Factors
dc.subjectPTEN
dc.subjectbiochemical recurrence
dc.subjectcastration-resistant prostate cancer
dc.subjectprostate cancer
dc.subjectprostate cancer-specific mortality
dc.subjectClinical Epidemiology
dc.subjectNeoplasms
dc.subjectUrology
dc.titlePTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
dc.typeJournal Article
dc.source.journaltitleInternational journal of urology : official journal of the Japanese Urological Association
dc.source.volume21
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/ssp/212
dc.identifier.contextkey8390984
html.description.abstract<p>OBJECTIVES: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy.</p> <p>METHODS: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992-2006, biopsy samples were stained for PTEN expression by the PREZEON assay with > 10% staining reported as positive. Cox proportional hazards and log-rank models were used to assess the correlation between PTEN loss and clinical outcomes.</p> <p>RESULTS: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9-5.1, P = 0.10), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log-rank, P < 0.0001), and time from androgen deprivation therapy to castration-resistant prostate cancer (log-rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer.</p> <p>CONCLUSIONS: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.</p>
dc.identifier.submissionpathssp/212
dc.contributor.departmentSenior Scholars Program
dc.contributor.departmentSchool of Medicine
dc.source.pages1209-14
dc.contributor.studentPrabhakar Mithal


This item appears in the following Collection(s)

Show simple item record